Séverine Fagète | Vice President, Mammalian Cell Line Services
KBI Biopharma

Séverine Fagète, Vice President, Mammalian Cell Line Services, KBI Biopharma

Séverine is the Vice President of Mammalian Cell Line Development (CLD) at KBI Biopharma’s Geneva Facility. Prior to the operational consolidation with KBI, Séverine held multiple leadership roles with escalating responsibilities at Selexis. She brings nearly two decades of experience in the pharmaceutical industry, and deep expertise in early drug discovery, antibody engineering (bispecifics), stable cell line development, and project management. Séverine holds a master’s in biotechnology from L’Ecole Nationale Supérieure de Technologie des Biomolécules de Bordeaux (ENSTBB) and a PhD in protein engineering from University of Geneva, acquired through NovImmune (now Light Chain Bioscience). She subsequently held a postdoctoral position at the University of Geneva where she designed a novel phage display platform for accelerating bispecific antibody development.

Appearances:



Festival of Biologics Day 1 @ 17:10

Cultivating innovation: Evolving Cell Line Development for next-generation biotherapeutics

Advanced cell line development is critical to the success of biotherapeutic development, requiring high productivity, stability, and consistent performance from early stages through commercial manufacturing. Building on the Selexis® SUREtechnology™ foundation and CHO-M™ cell line, we have evolved our TranspoEase™ platform to enhance efficiency and flexibility. Our in-house engineered transposase drives improved integration and higher titers, while our novel Biselect multi-selection strategy ensures optimal chain pairing and strong expression of complex, multi-chain molecules without added vector design complexity. We also integrate developability assessment early in the workflow to support smarter candidate selection and reduce downstream risk. Looking ahead, we are redefining safety standards with the development of the first RVLP-low host cell line on the market—setting a new benchmark for next-generation biomanufacturing.

last published: 28/Apr/26 15:45 GMT

back to speakers

Get involved at Festival of Biologics Basel 2026

 

 

TO SPONSOR


Derek Cavanagh

Derek.Cavanagh@terrapinn.com

 

Jack Bebb
Jack.Bebb@terrapinn.com

 

TO SPEAK


Jack Beard
Jack.Beard@terrapinn.com

 

MARKETING & PRESS


Ollie McDaid

ollie.mcdaid@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.